Grufity logoGrufity logo

IDEXX Laboratories Inc Stock Research

IDXX

500.08USD+6.53(+1.32%)Market Closed

Market Summary

USD500.08+6.53
Market Closed
1.32%

IDXX Stock Price

IDXX RSI Chart

IDXX Valuation

Market Cap

41.5B

Price/Earnings (Trailing)

61.04

Price/Sales (Trailing)

12.31

EV/EBITDA

40.86

Price/Free Cashflow

105.17

IDXX Price/Sales (Trailing)

IDXX Profitability

Operating Margin

59.52%

EBT Margin

25.54%

Return on Equity

111.56%

Return on Assets

24.72%

Free Cashflow Yield

0.95%

IDXX Fundamentals

IDXX Revenue

Revenue (TTM)

3.4B

Revenue Y/Y

3.43%

Revenue Q/Q

-1.56%

IDXX Earnings

Earnings (TTM)

679.1M

Earnings Y/Y

5.8%

Earnings Q/Q

-4.83%

Price Action

52 Week Range

317.06558.01
(Low)(High)

Last 7 days

3%

Last 30 days

6.6%

Last 90 days

22.6%

Trailing 12 Months

-8.6%

IDXX Financial Health

Current Ratio

0.89

IDXX Investor Care

Buy Backs (1Y)

1.97%

Diluted EPS (TTM)

8.03

Peers (Alternatives to IDEXX Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.6B
31.5B
2.72% -13.99%
25.46
5.83
6.85% 12.06%
177.5B
43.7B
0.43% -13.32%
25.6
4.07
1.34% -1.95%
107.3B
30.8B
-1.78% -26.78%
26.38
3.49
-3.19% -17.38%
41.5B
3.4B
6.60% -8.59%
61.04
12.31
4.73% -8.83%
25.7B
2.9B
8.86% -15.64%
43.82
8.89
1.95% -11.47%
MID-CAP
10.6B
847.1M
7.86% 25.46%
-5.3K
12.54
13.32% -137.89%
5.7B
935.1M
12.97% 49.27%
202.4
6.08
119.91% 139.38%
4.0B
630.7M
0.87% -39.95%
-246.65
6.35
25.40% -128.45%
3.7B
-
4.25% -20.78%
3.27
1.42
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.2B
237.3M
8.94% -31.25%
-25.59
4.89
6.59% 84.02%
1.0B
257.3M
14.46% -29.40%
-50.89
3.93
1.41% -1632.49%
45.5M
7.9M
3.13% -64.81%
-1.47
5.78
23.02% -7.81%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

Financials for IDEXX Laboratories

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.8%3,3673,3403,3093,2743,215
Cost Of Revenue-0.1%1,3631,3641,3661,3571,326
Gross Profit1.4%2,0041,9761,9421,9171,889
  S&GA Expenses0.7%525521515504487
  R&D Expenses-0.7%255257249164161
EBITDA2.9%1,0129839621,039-
EBITDA Margin2.1%0.30*0.29*0.29*0.32*-
Earnings Before Taxes2.5%860839823904903
EBT Margin1.7%0.26*0.25*0.25*0.28*-
Interest Expenses18.0%40.0034.0030.0029.0030.00
Net Income1.4%679670664735745
Net Income Margin0.6%0.20*0.20*0.20*0.22*-
Free Cahsflow-12.0%394448439615-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets4.0%2,7472,6402,6072,5932,437
  Current Assets4.0%1,1011,0591,0431,090956
    Cash Equivalents13.5%11399.00114205144
  Inventory3.6%368355333302269
  Net PPE6.1%649612594593588
  Goodwill1.8%362355356361359
Liabilities-1.2%2,1382,1642,1501,9531,747
  Current Liabilities3.9%1,2361,1901,167971764
    LT Debt, CurrentInfinity%75.00---75.00
    LT Debt, Non Current-8.7%694761768773775
Shareholder's Equity27.9%609476457640690
  Retained Earnings5.0%3,6003,4273,2463,1142,920
  Additional Paid-In Capital1.8%1,4631,4381,4201,4001,377
Shares Outstanding-0.1%83.0083.0083.0084.0085.00
Minority Interest------
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-6.3%543580578746756
  Share Based Compensation7.7%50.0046.0043.0040.0038.00
Cashflow From Investing-2.7%-195-190-190-310-292
Cashflow From Financing11.7%-370-420-492-581-697
  Buy Backs-17.2%820990999881747

Risks for IDXX

What is the probability of a big loss on IDXX?

61.9%


Probability that IDEXX Laboratories stock will be more than 20% underwater in next one year

37.7%


Probability that IDEXX Laboratories stock will be more than 30% underwater in next one year.

18.5%


Probability that IDEXX Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IDXX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if IDEXX Laboratories was unfortunately bought at previous high price.

Drawdowns

Returns for IDXX

Cumulative Returns on IDXX

27.1%


10-Year Cumulative Returns

30.1%


7-Year Cumulative Returns

21.2%


5-Year Cumulative Returns

27.3%


3-Year Cumulative Returns

What are the long-term rolling returns for IDXX?

FIve years rolling returns for IDEXX Laboratories.

Annualized Returns

Which funds bought or sold IDXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-2.63
1,825,530
10,153,300
0.08%
2023-03-23
ETF MANAGERS GROUP, LLC
reduced
-57.71
-471,060
529,940
0.03%
2023-03-17
American Portfolios Advisors
reduced
-7.3
-34,692
215,028
0.01%
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-16.66
20,198
502,198
0.01%
2023-03-13
Claro Advisors LLC
new
-
1,019,080
1,019,080
0.33%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
6.1
15,074,100
60,943,100
0.07%
2023-03-06
Rockefeller Capital Management L.P.
added
0.16
4,271,000
21,074,000
0.11%
2023-03-03
TIAA, FSB
reduced
-0.88
170,522
877,522
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
sold off
-100
-
-
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
62,685,500
62,685,500
0.78%

1–10 of 50

Latest Funds Activity

Are funds buying IDXX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own IDXX
No. of Funds

IDEXX Laboratories News

Defense World

IDEXX Laboratories (NASDAQ:IDXX) Lifted to “Buy” at StockNews.com.

Defense World,
80 minutes ago

London South East

Nasdaq

Stock Traders Daily

How To Trade Idexx Laboratories $IDXX.

Stock Traders Daily,
13 days ago

Schedule 13G FIlings of IDEXX Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 09, 2023
vanguard group inc
9.82%
8,132,479
SC 13G/A
Jan 26, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Jan 20, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Feb 10, 2022
vanguard group inc
9.34%
7,923,466
SC 13G/A
Jan 27, 2022
blackrock inc.
10.6%
8,990,586
SC 13G/A
Jan 25, 2022
blackrock inc.
10.6%
8,990,586
SC 13G/A
Sep 09, 2021
blackrock inc.
10.1%
8,612,405
SC 13G/A
Feb 12, 2021
fundsmith llp
4.95%
4,226,428
SC 13G/A

IDXX Fair Value

IDEXX Laboratories fair value in different scenarios

The table shows the Fair Value estimates for IDEXX Laboratories for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

128.06

-74.39%

159.72

-68.06%

215.71

-56.86%

276.87

-44.63%

328.25

-34.36%
Current Inflation

116.97

-76.61%

143.80

-71.24%

190.52

-61.90%

241.44

-51.72%

284.14

-43.18%
Very High Inflation

103.31

-79.34%

124.60

-75.08%

160.87

-67.83%

200.38

-59.93%

233.47

-53.31%

Historical IDEXX Laboratories Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of IDEXX Laboratories

View All Filings
Date Filed Form Type Document
Mar 31, 2023
ARS
ARS
Mar 31, 2023
DEF 14A
DEF 14A
Mar 31, 2023
DEFA14A
DEFA14A
Feb 21, 2023
4
Insider Trading
Feb 17, 2023
4
Insider Trading
Feb 17, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading

Latest Insider Trading transactions for IDXX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-16
JUNIUS DANIEL M
acquired
451,878
206
2,187
-
2023-02-16
AYERS JONATHAN W
gifted
-
-
-1,000
-
2023-02-16
Turner Kathy V
acquired
795
79.54
10.00
senior vice president
2023-02-16
JUNIUS DANIEL M
sold
-1,119,040
511
-2,187
-
2023-02-16
Turner Kathy V
sold
-5,155
515
-10.00
senior vice president
2023-02-15
Turner Kathy V
acquired
79,540
79.54
1,000
senior vice president
2023-02-15
Turner Kathy V
sold
-510,031
510
-1,000
senior vice president
2023-02-14
Hunt Nimrata
sold (taxes)
-120,372
503
-239
executive vice president
2023-02-14
Hunt Nimrata
acquired
-
-
791
executive vice president
2023-02-14
Underberg Sharon E.
acquired
-
-
1,010
evp, gc & corp. secretary

1–10 of 50

Jonathan J. Mazelsky
10400
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 3,367,324$ 3,215,360$ 2,706,655
Cost of Revenue:   
Total cost of revenue1,362,9861,325,9281,135,615
Gross profit2,004,3381,889,4321,571,040
Expenses:   
Sales and marketing524,505486,735434,435
General and administrative326,248309,660300,832
Research and development254,820161,009141,249
Income from operations898,765932,028694,524
Interest expense(39,858)(29,808)(33,125)
Interest income1,065434586
Income before provision for income taxes859,972902,654661,985
Provision for income taxes180,883157,81079,854
Net income679,089744,844582,131
Less: Net (loss) income attributable to noncontrolling interest0(1)355
Net income attributable to IDEXX Laboratories, Inc. stockholders$ 679,089$ 744,845$ 581,776
Earnings per Share:   
Basic (in USD per share)$ 8.12$ 8.74$ 6.82
Diluted (in USD per share)$ 8.03$ 8.60$ 6.71
Weighted Average Shares Outstanding:   
Basic (in shares)83,62385,20085,342
Diluted (in shares)84,60086,57286,722
Product revenue   
Revenue:   
Total revenue$ 1,928,773$ 1,875,308$ 1,586,809
Cost of Revenue:   
Total cost of revenue656,511656,823557,795
Service revenue   
Revenue:   
Total revenue1,438,5511,340,0521,119,846
Cost of Revenue:   
Total cost of revenue$ 706,475$ 669,105$ 577,820

IDXX Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 112,546,000$ 144,454,000
Accounts receivable, net of allowance of $8,265 in 2022 and $5,668 in 2021400,619,000368,348,000
Inventories367,823,000269,030,000
Other current assets220,489,000173,823,000
Total current assets1,101,477,000955,655,000
Long-Term Assets:  
Property and equipment, net649,474,000587,667,000
Operating lease right-of-use assets118,618,000105,101,000
Goodwill361,795,000359,345,000
Intangible assets, net97,672,00099,035,000
Other long-term assets417,729,000330,400,000
Total long-term assets1,645,288,0001,481,548,000
TOTAL ASSETS2,746,765,0002,437,203,000
Current Liabilities:  
Accounts payable110,221,000116,140,000
Accrued liabilities433,662,000458,909,000
Credit facility579,000,00073,500,000
Current portion of long-term debt74,982,00074,996,000
Current portion of deferred revenue37,938,00040,034,000
Total current liabilities1,235,803,000763,579,000
Long-Term Liabilities:  
Deferred income tax liabilities8,150,0008,935,000
Long-term debt, net of current portion694,387,000775,205,000
Long-term deferred revenue, net of current portion30,862,00041,174,000
Long-term operating lease liabilities101,239,00087,377,000
Other long-term liabilities67,587,00070,941,000
Total long-term liabilities902,225,000983,632,000
Total liabilities2,138,028,0001,747,211,000
Commitments and Contingencies (Note 16)
Stockholders’ Equity:  
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,193 shares in 2022 and 106,878 shares in 2021; Outstanding: 82,894 shares in 2022 and 84,562 shares in 202110,719,00010,688,000
Additional paid-in capital1,463,215,0001,377,320,000
Deferred stock units: Outstanding: 58 units in 2022 and 90 units in 20215,182,0005,719,000
Retained earnings3,599,529,0002,920,440,000
Accumulated other comprehensive loss(77,796,000)(53,484,000)
Treasury stock, at cost: 24,299 shares in 2022 and 22,317 shares in 2021(4,392,112,000)(3,570,691,000)
Total IDEXX Laboratories, Inc. stockholders’ equity608,737,000689,992,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 2,746,765,000$ 2,437,203,000